Department of Pharmaceutical Sciences, Mahatma Gandhi Vidyamandir's Pharmacy College, Panchavati, Nashik, 422 003 Maharashtra, India.
Int J Antimicrob Agents. 2020 Aug;56(2):105984. doi: 10.1016/j.ijantimicag.2020.105984. Epub 2020 Apr 17.
Despite advances in drug discovery, viral infections remain a major challenge for scientists across the globe. The recent pandemic of COVID-19 (coronavirus disease 2019), caused by a viral infection with SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2), has created a disastrous situation all over the world. As no drugs are available to treat this life-threatening disease and the mortality rate due to COVID-19 is high, there is an utmost need to attempt to treat the infection using drug repurposing. Some countries are against the use of these drugs because of adverse effects associated with drug repurposing and lack of statistically significant clinical data, but they have been found to be effective in some countries to treat COVID-19 patients (off-label/investigational). This article emphasises possible drug candidates in the treatment of COVID-19. Most of these drugs were found to be effective in in vitro studies. There is a need to re-assess in vitro data and to carry out randomised clinical trials. Further investigations of these drugs are recommended on a priority basis.
尽管在药物发现方面取得了进展，但病毒感染仍然是全球科学家面临的主要挑战。最近的 COVID-19（2019 年冠状病毒病）大流行是由 SARS-CoV-2（严重急性呼吸系统综合症冠状病毒 2）引起的病毒性感染造成的，给全世界带来了灾难性的局面。由于没有治疗这种危及生命的疾病的药物，而且 COVID-19 的死亡率很高，因此急需尝试使用药物重新定位来治疗感染。一些国家反对使用这些药物，因为药物重新定位与不良影响有关，而且缺乏统计学上有意义的临床数据，但在一些国家发现它们对治疗 COVID-19 患者（超适应证/研究性）有效。本文强调了治疗 COVID-19 的可能药物候选物。这些药物中的大多数在体外研究中被发现是有效的。需要重新评估体外数据并进行随机临床试验。建议优先对这些药物进行进一步调查。
